MedTrace Logo

Domperidone for Chronic Nausea and Vomiting

NCT02757534 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2020-05-05

No results posted yet for this study

Summary

The purpose of this study is to provide oral domperidone to patients with gastroparesis, between the ages of 18 and 60 years of age, who have failed standard treatment. Standard therapy at the University of Iowa is eating blended foods, liquid diet, Eryped syrup (125 mg TID) 30 minutes before meals, or reglan (20 mg BID).

Conditions

Interventions

DRUG

Domperidone

The study drug will be given to relieve the symptoms of gastroparesis, including nausea and vomiting.

Sponsors & Collaborators

  • Yehudith Assouline-Dayan

    lead OTHER

Principal Investigators

  • Yehudith Assouline-Dayan, MD · University of Iowa

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02757534 on ClinicalTrials.gov